sábado, 21 de noviembre de 2026

The grim human cost of the Trump—RFK Jr. measles-prevention failure: 16 times more cases than in 2024 Mauro Proença | November 19, 2026

https://geneticliteracyproject.org/2026/11/19/the-grim-human-cost-of-the-trump-rfk-jr-measles-prevention-failure-16-times-more-cases-than-in-2024/ Measles was once a public health success story, eliminated from the United States more than a quarter-century ago. Now, with cases surging, vaccination rates falling, and the loss of the nation’s elimination status, a preventable disease is making an unwelcome comeback. The question is no longer simply why parents hesitate to vaccinate, but whether misinformation, institutional distrust, and conflicting messages from public health leaders are making that hesitation harder to overcome.

Health vs. Hype’s rocky debut: American Medical Association’s misinformation-debunking podcast platforms ‘leaky gut’ wellness crank MedPage Today | November 19, 2026

https://geneticliteracyproject.org/2026/11/19/health-vs-hypes-rocky-debut-american-medical-associations-misinformation-debunking-podcast-platforms-leaky-gut-wellness-crank/ The American Medical Association has finally stepped into the misinformation ring with its new podcast, Health vs. Hype — but its gut-health episode left many in the scientific community scratching their heads, Katie Suleta argues in an opinion piece for MedPage Today. The show has taken on creatine, protein-maxxing and detoxes, which the author calls “a long-overdue and vital institutional response.” In late October, though, host Trace Dominguez interviewed Danielle Brown, a nutrition influencer and self-described holistic nutritionist, for an episode on sea moss, leaky gut and probiotics. Gastroenterologist Mohamed Mokadem, MD, then joined to address her claims.

Why should thousands of Americans die every year waiting for a kidney transplant? There’s an easy fix to this morbid reality Wall Street Journal | November 19, 2026

https://geneticliteracyproject.org/2026/11/19/why-should-thousands-of-americans-die-every-year-waiting-for-a-kidney-transplant-theres-an-easy-fix-to-this-morbid-reality/ Legally rewarding living kidney donors through the tax code could shrink a waiting list that kills roughly 12 Americans a day, argues psychiatrist Sally Satel in an opinion piece for The Wall Street Journal. Satel speaks from experience: friends donated kidneys to her in 2006 and 2016. Living donors account for about 1 in 3 kidney recipients. Everyone else depends on the national waiting list run by the United Network for Organ Sharing (UNOS), which has never met demand. When Satel got her first kidney, about 70,000 other patients were still waiting.

Viewpoint: The dangerous lie RFK Jr.-founded Children’s Health Defense is circulating to discredit one of medicine’s great breakthroughs: the MMR (measles-mumps-rubella) vaccine Stop AntiVax Propaganda | November 19, 2026

https://geneticliteracyproject.org/2026/11/19/viewpoint-the-dangerous-lie-rfk-jr-founded-childrens-health-defense-is-circulating-to-discredit-one-of-medicines-great-breakthroughs-the-mmr-measles-mumps-rubella-vaccine/ Not surprisingly, with the announcement of yet another measles death, as if on cue, Children’s Health Defense is spreading another myth about MMR vaccine deaths.

Crunchy Moms disinformation flood: Zuckerberg’s Facebook has opened floodgates on measles and vaccines The Guardian | November 20, 2026

https://geneticliteracyproject.org/2026/11/20/crunchy-moms-disinformation-flood-zuckerbergs-facebook-has-opened-floodgates-on-measles-and-vaccines/ Facebook isn’t just tolerating dangerous vaccine misinformation in its groups — it’s steering users toward it, as The Guardian’s Michelle R Smith reports. Her investigation centers on Crunchy Moms, a public group of more than 490,000 members where commenters routinely call vaccines “poison” and insist they cause autism and sudden infant death syndrome (SIDS). The stakes aren’t abstract. When a Lancaster County, Pennsylvania, parent asked in August whether to vaccinate their three-year-old during a measles outbreak, members replied that children “cannot die of measles.” Pennsylvania has reported six measles-associated deaths this year, including two babies in Lancaster County. Meta’s own AI then summarized the 589 replies, noting commenters “claim the vaccine is unnecessary or even harmful.”

US initiative targets $200M to accelerate therapeutic cancer vaccines The National Cancer Institute and Foundation for the NIH are seeking $200 million to support clinical trials, develop new vaccine platforms, and build a shared data resource. Written byBree Foster, PhD

US initiative targets $200M to accelerate therapeutic cancer vaccines The National Cancer Institute and Foundation for the NIH are seeking $200 million to support clinical trials, develop new vaccine platforms, and build a shared data resource. Written byBree Foster, PhD https://www.drugdiscoverynews.com/us-initiative-targets-200m-to-accelerate-therapeutic-cancer-vaccines-17676 On November 11th, data from the INTerpath-001 Phase 3 trial provided the first clinical evidence that a personalized mRNA cancer vaccine can improve outcomes when combined with immunotherapy. The encouraging results have prompted a new US public–private initiative to accelerate the development of therapeutic cancer vaccines across multiple tumor types. The National Cancer Institute (NCI) and the Foundation for the National Institutes of Health (FNIH) are establishing a $200 million Therapeutic Cancer Vaccines Initiative (TCVI) to advance promising vaccine candidates into clinical testing.

Pfizer steps into in vivo CAR T space with $2.6B licensing deal FDA approvals, trial updates, and more led the news this week. Brought to you byDDN editorial team

Pfizer steps into in vivo CAR T space with $2.6B licensing deal FDA approvals, trial updates, and more led the news this week. Brought to you byDDN editorial team https://www.drugdiscoverynews.com/weekly-rundown-pfizer-steps-into-in-vivo-car-t-space-with-2-6b-licensing-deal-17675 On Wednesday, Pfizer announced an exclusive licensing deal with Starna Therapeutics, giving Pfizer the rights to three in vivo pre-IND CAR-T autoimmune programs. Under the agreement, Starna will receive an upfront payment of $330 million, with the potential to earn up to $2.3 billion in milestone payments and royalties on net sales of any approved products. The deal comes amidst a flood of patents that will expire for Pfizer in the next few years, and marks Pfizer’s first foray into the in vivo CAR-T space. “In vivo CAR-T is an emerging and promising approach for treating autoimmune diseases, and the patients who might benefit most are those for whom today’s options fall short. Pfizer has significant experience in developing and manufacturing RNA-based medicines globally, and Starna’s in vivo CAR-T programs and technology give us a powerful way to pursue these approaches,” said Michael Vincent, Chief Inflammation & Immunology Officer at Pfizer, in the press release. – Allison Whitten

Stepwise Clinical Management for AL Amyloidosis: A Practical Algorithm Authors: Pedro Vianna, MD; Ashutosh Wechalekar, MD; Efstathios Kastritis, MD, PhD; Vaishali Sanchorawala, MD

https://www.medscape.org/viewarticle/stepwise-clinical-management-al-amyloidosis-practical-2026a1000tzd?page=1&src=mkmcmr_driv_stan_mscpedu_261120-OUS-HONC-stepwise-clinical-management-al-amyloidosis-practical-2026a1000tzd-cta&uac=148436CN

Clinical Turning Points Decisions That Shape Care Across the Spectrum of Systemic Mastocytosis CME/CNE/CPE New Orleans Ernest N. Morial Convention Center Friday, December 11, 2026 | 7:30 pm - 9:00 pm CT Hybrid

https://na.eventscloud.com/website/98569/ Systemic mastocytosis (SM) is a rare hematologic disorder that often presents with a wide variety of nonspecific symptoms. Despite advances in the diagnosis and growing awareness of SM, the full patient burden of nonadvanced SM (nonAdvSM) remains underrecognized and underaddressed in clinical practice. Join us for this interactive 90-minute CME/CE symposium featuring livestreaming and social media simulcast. Expert faculty will examine critical clinical turning points to overcome inertia and uncertainty, optimizing treatment decisions—particularly when considering escalation to disease-directed therapy. Walk away with practical strategies to evaluate disease control, integrate emerging clinical evidence, and optimize management across the SM continuum. Friday Satellite Symposium on Hematology, preceding the 68th ASH Annual Meeting and Exposition

ESMO ASIA 2026 INDUSTRY SATELLITE SYMPOSIUM Shaping the Future of HER2-Mutated Advanced NSCLC: Precision Strategies Across the Continuum CME/CNE Suntec Singapore Convention & Exhibition Centre Friday, 4 December 2026 | 12:30 - 14:00 SGT In-Person

https://events.medscapelive.org/website/100421/?utm_campaign=449165.01a_inperson_awarenessemail&utm_source=lbu-edu&utm_medium=em&utm_content=ext&ecd=em_ext_261116_lbu-edu_449165.01-44916501ainpersonawarenessemail_ Recent breakthroughs in HER2-directed therapies are transforming the standard of care for patients with HER2-mutated advanced non–small cell lung cancer (NSCLC). Join our distinguished panel of experts for a highly engaging symposium to learn more about the effective implementation of novel, evidence-based therapeutic strategies and how to optimally manage your patients across the care continuum. IMPORTANT NOTICE: To attend this symposium in person, you must register directly with the ESMO ASIA CONGRESS 2026. Please visit the official congress website for more details.

New brain mapping tool reveals how neurons independently calculate motion

https://www.news-medical.net/news/20261120/New-brain-mapping-tool-reveals-how-neurons-independently-calculate-motion.aspx A ball flying toward your head, a car approaching as you cross the street, or - in caveman days - a predator suddenly appearing. To react quickly, your brain needs to instantly know not only that something is moving, but which way it's going. Scientists have long known that certain cells in the eye activate only when something moves in a particular direction, and they assumed the brain simply received that information directly from those eye cells. But no tool existed to confirm this hypothesis by mapping out the precise connections between cells in the eye and those in the brain. Now, researchers at UC San Francisco have developed a new brain-mapping tool to trace these connections. They used the technology to show that the brain doesn't just take the eye's word for the direction of motion; some cells in the brain also compute it on their own.

Implanted device offers new treatment option for rheumatoid arthritis

https://www.news-medical.net/news/20261120/Implanted-device-offers-new-treatment-option-for-rheumatoid-arthritis.aspx A new treatment for rheumatoid arthritis that uses a small, implanted device to help control inflammation is now available to patients in Michigan through Henry Ford Health's neurosurgery team. The wireless device, about the size of a multivitamin, is implanted on the vagus nerve and uses electrical stimulation to activate the body's natural response to inflammation, helping ease the inflammation that causes joint pain, swelling and stiffness in rheumatoid arthritis. Dr. Ellen Air, functional neurosurgeon and chair of the Department of Neurosurgery at Henry Ford Health, completed the state's first commercial implantation of the device on Oct. 26 at Henry Ford Hospital in Detroit. The patient, Kim Landrith, 71, of Macomb County, had the device activated Nov. 11.

Beyond Chemotherapy: Integrating Novel Targeted Agents Into Platinum-Resistant Ovarian Cancer Clinical Practice Authors: Susana Banerjee, MBBS, PhD, FRCP; Nicoletta Colombo, MD, PhD; Christian Marth, MD, PhD

https://www.medscape.org/viewarticle/beyond-chemotherapy-integrating-novel-targeted-agents-2026a100179c?page=1&src=wnl_tpal_261121_mscpedu&uac=148436CN&impID=8927815

Translating Molecular Insights Into Practice for HR-Positive/HER2-Negative Metastatic Breast Cancer Authors: Hope Rugo, MD; Peter A. Fasching, MD

https://www.medscape.org/viewarticle/translating-molecular-insights-practice-hr-positive-her2-2026a1000y0g?page=1&src=mkmcmr_driv_stan_mscpedu_261121-OUS-HONC-translating-molecular-insights-practice-hr-positive-her2-2026a1000y0g-cta&uac=148436CN

Conversations on Pain: Determining the Causes, Making a Plan, and Considering Nonopioid Analgesics Authors: Jeff Gudin, MD; Timothy J. Atkinson, PharmD, CPE; Antje Barreveld, MD; Mark Garofoli, PharmD, MBA, BCGP, CPE, CTTS; Steven P. Stanos, DO

https://www.medscape.org/viewarticle/conversations-pain-determining-causes-making-plan-and-2025a1000wsc?page=1&uac=148436CN&src=mkm_driv_cust_mscpedu_261121-12110769

New drug combo shrinks tumors in most patients facing aggressive cancer type (+... +)

New drug combo shrinks tumors in most patients facing aggressive cancer type https://www.foxnews.com/health New drug combo shrinks tumors in most patients facing aggressive cancer type Tumors disappeared entirely in 8.2% of patients, and 90.2% saw cancer growth stop By Khloe Quill Fox News Published November 20, 2026 8:07pm EST https://www.foxnews.com/health/new-drug-combo-shrinks-tumors-most-patients-aggressive-cancer-type

University students are biggest spreaders of COVID Undergraduates were the first group to spread genetic variants of SARS-CoV-2 during the pandemic, mega-analysis finds. By Heidi Ledford

https://www.nature.com/articles/d41586-026-03746-0?utm_source=Live+Audience&utm_campaign=830173f56d-nature-briefing-daily-20261120&utm_medium=email&utm_term=0_-33f35e09ea-50432164 Universities have become hotbeds of SARS-CoV-2 transmission, according to a massive analysis of more than 85,000 viral genome sequences and other data collected from people with COVID-19.

People entering old age now have better memory than their parents did Older people today maintain memory function for longer than previous generations did, according to a study of 219,000 adults. By Miryam Naddaf

https://www.nature.com/articles/d41586-026-03783-9?utm_source=Live+Audience&utm_campaign=830173f56d-nature-briefing-daily-20261120&utm_medium=email&utm_term=0_-33f35e09ea-50432164 People born later in the twentieth century have a better memory when they enter old age and experience slower cognitive decline than do those born earlier, according to a study1 published in Nature Medicine on 17 November. The analysis offers clues about why dementia rates have fallen by 13% per decade over the past 27 years in Europe and the United States2.

Dissecting the Evidence: Interpreting Recent Clinical Trial Data for Radiopharmaceutical-Based Combinations in Metastatic Castration-Resistant Prostate Cancer Authors: Bertrand Tombal, MD, PhD; Alicia K. Morgans, MD, MPH, FASCO

https://www.medscape.org/viewarticle/dissecting-evidence-interpreting-recent-clinical-trial-data-2026a10009un?page=1&uac=148436CN&src=mkmcmr_driv_stan_mscpedu_261120-OUS-HONC-dissecting-evidence-interpreting-recent-clinical-trial-data-2026a10009un-cta

Redefining the Patient Journey: The Promise and Practice in NTRK Fusion–Positive Cancers Authors: Theodore W. Laetsch, MD; Nicole A. Cipriani, MD; Herbert H. Loong, MBBS; Jonathan C. Trent, MD, PhD

https://www.medscape.org/viewarticle/redefining-patient-journey-promise-and-practice-ntrk-fusion-2026a1000lot?page=1&src=mkmcmr_driv_stan_mscpedu_261121-OUS-HONC-redefining-patient-journey-promise-and-practice-ntrk-fusion-2026a1000lot-cta&uac=148436CN

viernes, 20 de noviembre de 2026

Sugar from gut bacterium helps burn harmful visceral fat

https://www.news-medical.net/news/20261119/Sugar-from-gut-bacterium-helps-burn-harmful-visceral-fat.aspx Scientists have discovered that a sugar produced by a gut bacterium can increase energy burning in visceral fat-the harmful fat that accumulates around internal organs-while reducing weight gain and improving metabolic health, offering a potential new approach to tackling obesity. Their findings come as concerns over rising obesity rates continue to grow, with half of the world's population expected to be overweight or obese by 2035. In Singapore, over 12 per cent of the country's population is living with obesity. In the study, published in Cell Host & Microbe, researchers from Duke-NUS Medical School and Duke University School of Medicine identified a bacterium, Clostridium immunis (C. immunis), which lives in the gut. The team discovered that C. immunis produces a sugar molecule known as an exopolysaccharide (EPS). This sugar requires a small chemical group called phosphocholine for activity. This phosphocholine-modified sugar-like an "on switch"-catalyses the reduction of weight gain and visceral fat, which is closely linked to metabolic diseases such as type 2 diabetes and cardiovascular disease.

Menopause relief without hormones? Here’s what experts say actually works

From targeted medications and clinical hypnosis to dietary changes and herbal supplements, European menopause experts examine which hormone-free treatments hold the strongest scientific evidence for symptom relief. https://www.news-medical.net/news/20261119/Menopause-relief-without-hormones-Heree28099s-what-experts-say-actually-works.aspx In a recent consensus statement published in the journal Gynecological Endocrinology, an international expert panel from the European Society of Gynecology (ESG) reviewed evidence on non-hormonal interventions to manage menopausal symptoms in women with medical contraindications to, or who prefer not to use, menopausal hormone therapy (MHT).

Headaches linked to 70% higher odds of hearing loss in later life

https://www.news-medical.net/news/20261119/Headaches-linked-to-7025-higher-odds-of-hearing-loss-in-later-life.aspx Could a common neurological symptom offer clues about hearing health as we age? Researchers examine seven years of health survey data to explore a potential connection with implications for community hearing screening. In a study published in the journal BMC Public Health, researchers analyzed long-term health data from China and South Korea to examine whether self-reported headaches are associated with self-reported hearing loss in later life. Scientists from Guangzhou University of Chinese Medicine and its First Affiliated Hospital, the Lingnan Institute of Otolaryngology, and Guangdong Second Traditional Chinese Medicine Hospital in Guangzhou, China, conducted the research.

Continuing advanced therapies before surgery linked to fewer Crohn's complications

https://www.news-medical.net/news/20261119/Continuing-advanced-therapies-before-surgery-linked-to-fewer-Crohns-complications.aspx Patients with Crohn's disease who continue advanced therapies, including biologics and small-molecule drugs, in the months before elective colorectal surgery may have a lower risk of two postoperative complications: anastomotic leak and organ space surgical site infection, according to a study published in the Journal of the American College of Surgeons. These findings challenge previous thoughts that immunosuppressive therapies should be stopped before surgery due to concerns about postoperative complications. In contrast, advanced therapy use was associated with improved outcomes and lower risk of anastomotic leak and organ space surgical site infection, a feared complication of colorectal surgery.

Exposing hidden immune vulnerabilities in KRAS-mutant non-small cell lung cancer

https://www.news-medical.net/news/20261120/Exposing-hidden-immune-vulnerabilities-in-KRAS-mutant-non-small-cell-lung-cancer.aspx In a series of experiments, researchers have found that an experimental MYC inhibitor drug not only targets lung cancer cells directly but also makes cancer cells easier for the immune system to target and kill. MYC is a protein that is known to malfunction in cancer, allowing cells to grow and divide uncontrollably. However, until recently, researchers have struggled to find a way to target MYC. The experimental drug OMO-103 was designed to inhibit MYC and is already being tested with patients in clinical trials. The new research, to be presented on Friday at the 38th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics in Barcelona, Spain, shows that OMO-103 also seems to enable white blood cells to find and destroy cancer cells.

Most Read Cancer Science & Oncogenesis (+...)

https://read.qxmd.com/collection/1133?ecd=wnl_readmost_261120

Large NIH-supported study identifies key underlying pathways in endometriosis Findings shed light on genetic associations and mechanisms driving complex disorder.

https://www.nih.gov/news-events/news-releases/large-nih-supported-study-identifies-key-underlying-pathways-endometriosis U.S. Department of Health and Human Services NATIONAL INSTITUTES OF HEALTH NIH News National Institutes of Health For Immediate Release: Friday, November 20, 2026 CONTACT: NIH Office of Communications, LARGE NIH-SUPPORTED STUDY IDENTIFIES KEY UNDERLYING PATHWAYS IN ENDOMETRIOSIS Findings shed light on genetic associations and mechanisms driving complex disorder In a large, international study analyzing data from over 1 million people, researchers supported by the National Institutes of Health (NIH) identified multiple genomic regions, associations, and pathways underlying endometriosis, a debilitating, chronic condition in which tissue similar to the lining of the uterus grows in other places in the body. Endometriosis affects up to 1 in 10 women worldwide, it can lead to severe pain and fertility challenges, and it may be associated with risk for other diseases. The findings, published in Nature Genetics, provide insights that could someday lead to studies on potential targets for therapeutic interventions for this complex condition. “The findings from this large multi-ancestry study provide a wealth of information on the genetic underpinnings of endometriosis, a severely painful condition for which NIH is actively pursuing a cure,” said John Gaitanis, M.D., director of NIH’s Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD), which supported the study. “A greater understanding will help us take steps toward developing diagnostic tools and treatments to address this devastating disease.” Despite its prevalence, researchers still need to learn more about why and how endometriosis develops. Researchers have previously used genome-wide association studies to look for genes and pathways linked with endometriosis. However, these studies have primarily included populations with European ancestry, with some East Asian populations at a smaller scale. In the new study, the research team conducted a meta-analysis of endometriosis spanning 14 biobanks worldwide, representing over 1 million participants. Over 30% of those were of non-European ancestry. The researchers used a phenotyping approach, looking at a wide variety of cases of endometriosis, and looked for genetic associations and risk factors shared with other diseases. They also conducted further “multi-omic” analyses, looking at several kinds of biological data to identify genes associated with endometriosis. The researchers detected 58 genomic regions linked to endometriosis, including 27 that had not been recognized before. By studying people of African ancestry and Admixed-American ancestry (or groups with mixed North, Central, and South American heritage), the team found genetic links to endometriosis that had not been seen before. They found that endometriosis shares genetic links with 135 other health conditions or traits. Finally, through the multi-omic analyses, they identified 314 genes that may be associated with endometriosis. Together, these findings offer a bigger picture of endometriosis than was previously available and could lead to studies looking at the function of the mechanisms driving the disease. “By studying many types of biological data across people with different ancestries, we were able to increase our understanding of how endometriosis develops and affects the body,” said Shefali Setia-Verma, Ph.D., senior author of the study and Assistant Professor of Pathology and Laboratory Medicine at the University of Pennsylvania Perelman School of Medicine. “Our findings will help guide future research that could eventually lead to better diagnosis, personalized risk assessment, and treatments that target the disease.” About the Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD): NICHD leads research and training to understand human development, improve reproductive health, enhance the lives of children and adolescents, and optimize abilities for all. About the National Institutes of Health (NIH): NIH, the nation's medical research agency, includes 27 Institutes and Centers and is a component of the U.S. Department of Health and Human Services. NIH is the primary federal agency conducting and supporting basic, clinical, and translational medical research, and is investigating the causes, treatments, and cures for both common and rare diseases. For more information about NIH and its programs, visit www.nih.gov. NIH...Turning Discovery into Health -- Registered, U.S. Patent and Trademark Office ### This NIH News Release is available online at:

Hypothalamic volume and cell-type changes in ageing and Alzheimer’s disease Doudou Yu, Jürgen Germann, Ghulam Murtaza, Kaitlyn H. Hajdarovic, Kelsey R. Babcock, Shiva Kazempour Dehkordi, Alexander C. Jackson, Ivana Delalle, Miranda E. Orr, Habil Zare, Ritambhara Singh, Michael J. MacCoss, William Stafford Noble, Andrei G. Vlassenko, Manu S. Goyal & Ashley E. Webb

https://www.nature.com/articles/s41586-026-11305-w Alterations in metabolism, stress response, sleep, circadian rhythms and neuroendocrine processes are key features of ageing and neurodegeneration1,2. These fundamental processes are regulated by the hypothalamus, yet how its functionally distinct subregions and cell types change during human ageing and Alzheimer’s disease (AD) remains largely unexplored. Here we present HypoAD, an atlas of the human hypothalamus in ageing and AD, including high-resolution magnetic resonance imaging from 458 individuals and single-nucleus RNA sequencing of 614,403 nuclei from young participants, patients with AD and age-matched non-dementia control participants. We show that hypothalamic subregions governing metabolism, stress and circadian rhythms are particularly vulnerable, showing notable changes in both volumes and gene expression during ageing and AD. At the molecular level, machine learning models identified the inflammatory response and regulators of circadian rhythms as key cellular predictors of AD. These signatures were reflected in specific cell types: microglia transitioned to a pro-inflammatory state, whereas inhibitory neurons within sleep-regulating and circadian-regulating hypothalamic subregions showed the most profound transcriptional alterations, including disruptions in ligand–receptor interactions and G-protein-coupled receptor signalling. HypoAD provides a high-resolution volumetric map and a transcriptomic atlas of the human hypothalamus in ageing and AD, relating lifestyle and behavioural changes to the relevant volumetric and molecular pathways. In addition, HypoAD provides a framework to investigate hypothalamic dysfunction and establishes a roadmap for targeted interventions aimed at mitigating physiological disruptions to potentially slow disease progression.

Researchers discover novel insulin independent pathway for muscle glucose uptake

https://www.news-medical.net/news/20261120/Researchers-discover-novel-insulin-independent-pathway-for-muscle-glucose-uptake.aspx Researchers at the University of Cincinnati College of Medicine have identified a previously unknown way the body's muscles absorb glucose from the blood - without insulin. The breakthrough findings from the lab of Judith A. Heiny, PhD, professor emerita in the Division of Neurobiology and Integrative Physiology in the Department of Biomedical Sciences, were recently published in the Nature Portfolio journal Communications Biology and could open the door to new treatments for diabetes, hyperglycemia and insulin resistance that directly target this pathway in muscle tissue.

GLP-1 Receptor Agonists in MASH (Fatty Liver Disease): Emerging Therapeutic Potential (+++)...

https://www.news-medical.net/health/GLP-1-Receptor-Agonists-in-MASH-(Fatty-Liver-Disease)-Emerging-Therapeutic-Potential.aspx Can treatments targeting appetite and glucose regulation also change the course of fatty liver disease? Clinical trials examine how these drugs alter liver inflammation and scarring. Metabolic dysfunction-associated steatohepatitis (MASH), formerly nonalcoholic steatohepatitis (NASH), is the inflammatory form of metabolic dysfunction-associated steatotic liver disease (MASLD), linked to obesity, insulin resistance, and metabolic dysfunction. Glucagon-like peptide-1 (GLP-1) receptor agonists have demonstrated therapeutic benefits through their effects on body weight, glucose regulation, and liver histology.1,2,3 MASH is characterized by excessive hepatic fat accumulation, inflammation, and hepatocellular ballooning, a form of liver cell swelling and injury, with or without fibrosis. It develops through interacting metabolic and inflammatory processes, including insulin resistance, lipid accumulation, and cellular injury. As fibrosis advances, the risk of serious liver-related complications increases.1,2,3 What Does Inflammation Do to the Body? https://www.news-medical.net/health/What-Does-Inflammation-Do-to-the-Body.aspx What is Fatty Liver? https://www.news-medical.net/health/What-is-Fatty-Liver.aspx

Which Drinkware Material Is Safest? Comparing Glass, Ceramic, Stainless Steel, and Plastics

https://www.news-medical.net/health/Which-Drinkware-Material-Is-Safest-Comparing-Glass-Ceramic-Stainless-Steel-and-Plastics.aspx What enters your drink beyond the beverage itself? Explore the science of chemical migration, hidden material exposures, and the factors that influence the safety of the containers we use every day. The selection of daily drinkware can affect exposure to endocrine-disrupting chemicals (EDCs), plastic particles, and heavy metal migration. Material composition, surface decoration, beverage chemistry, temperature, and contact time influence migration, though the contribution of drinkware to total chronic exposure remains uncertain.2,3 Contact between liquid media and container surfaces can allow migration or chemical leaching, defined as the transfer of substances from a container into its contents. Higher temperatures and longer contact times can increase migration, while acidic solutions can promote metal release from some products.

180 million people may harbor gut viruses that could explain the origins of smallpox (...)

https://www.news-medical.net/news/20261119/180-million-people-may-harbor-gut-viruses-that-could-explain-the-origins-of-smallpox.aspx A global survey of more than 85,000 metagenomic assemblies reveals an overlooked group of gut viruses that could hold clues to an evolutionary mystery stretching back 700 million years. A recent study published in the journal Nature identified a previously overlooked group of large DNA viruses, named egoviruses, that represent the closest known evolutionary relatives of poxviruses, the group that includes the virus responsible for smallpox. https://www.nature.com/articles/s41586-026-11283-z Closest relatives of poxviruses prevail in human and animal guts worldwide Morgan Gaïa, Ulysse Guyet, Hans-Joachim Ruscheweyh, A. Murat Eren, Shinichi Sunagawa, Eugene V. Koonin, Mart Krupovic & Tom O. Delmont

Emerging Therapies in Uveal Melanoma: Clinical Trial Updates Authors: Marlana Orloff, MD; Richard D. Carvajal, MD; Paul Nathan, PhD, FRCP

https://www.medscape.org/viewarticle/emerging-therapies-uveal-melanoma-clinical-trial-updates-2026a1000t9y?page=1&src=mkmcmr_driv_stan_mscpedu_261119-OUS-HONC-emerging-therapies-uveal-melanoma-clinical-trial-updates-2026a1000t9y-cta&uac=148436CN

Next-Generation Gadolinium-Based Contrast Agents in MRI: Quickfire Answers to Your Top Questions Authors: Taryn Winter Brill; Katja Pinker-Domenig, MD, PhD; Dipan J. Shah, MD, FACC

https://www.medscape.org/viewarticle/next-generation-gadolinium-based-contrast-agents-mri-2026a1000xjl?page=1&uac=148436CN&src=mkmcmr_driv_stan_mscpedu_261119-OUS-HONC-next-generation-gadolinium-based-contrast-agents-mri-2026a1000xjl-cta

Conversations on Pain: Determining the Causes, Making a Plan, and Considering Nonopioid Analgesics Authors: Jeff Gudin, MD; Timothy J. Atkinson, PharmD, CPE; Antje Barreveld, MD; Mark Garofoli, PharmD, MBA, BCGP, CPE, CTTS; Steven P. Stanos, DO

https://www.medscape.org/viewarticle/conversations-pain-determining-causes-making-plan-and-2025a1000wsc?page=1&uac=148436CN&src=mkm_driv_cust_mscpedu_261119-12110769

A consensus to stall on biodiversity The Lancet Planetary Health (++...)

A consensus to stall on biodiversity The Lancet Planetary Health https://www.thelancet.com/journals/lanplh/article/PIIS2542-5196(26)00141-5/fulltext?dgcid=raven_jbs_etoc_email In October this year, representatives met for the 17th Conference of the Parties to the Convention on Biological Diversity, and the results were to most a disappointment. The Convention — established in 1993 and signed by almost every country in the world — recognised more than 20 years ago that global biodiversity was in serious decline, and it was meant to provide the leading multilateral forum to solve that problem. Unfortunately, despite the recognition that biodiversity is essential to human health and wellbeing, it remains overall in decline. In 2010 countries negotiated the Aichi targets to protect and restore global biodiversity over the next decade, but by 2020 most of the targets remained unmet. This failure was blamed on the vagueness of the targets, not providing ways to monitor progress, and no clear plan to finance implementation. https://www.thelancet.com/journals/lanplh/issue/vol10no10/PIIS2542-5196(26)X2010-1

Multiple sclerosis: beyond controlling relapses The Lancet (++...)

Multiple sclerosis: beyond controlling relapses The Lancet https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(26)02345-7/fulltext?dgcid=raven_jbs_etoc_email Few neurological diseases have seen a transformation in diagnosis and treatment as remarkable as multiple sclerosis. A chronic, heterogeneous autoimmune condition, it typically begins in early adulthood and affects over 3 million people, with women roughly three times more likely to be affected than men. Characterised by inflammation, demyelination, axonal injury, and neuronal loss, multiple sclerosis can cause relapses and gradual accumulation of disability. Three decades ago, treatment options were few and far between; today, more than 20 disease-modifying therapies are available. These therapies can reduce the frequency of relapses and the development of new lesions detected with MRI. However, the success in controlling relapses has brought to light another challenge: despite otherwise effective treatment, some patients continue to accumulate disability. https://www.thelancet.com/journals/lancet/issue/vol408no10569/PIIS0140-6736(26)X2044-X

Oncology Perspective: Should Patients Have to Go on TV to Access Cancer Drugs?​

Oncology Perspective Should Patients Have to Go on TV to Access Cancer Drugs?​ Televised appeals for promising cancer drugs raise questions regarding equitable access, regional inequalities, and fair allocation of public healthcare resources. Medscape Europe, November 20, 2026 https://www.medscape.com/index/list_13293_0

Oncology News: Blinatumomab Feasible for Children With Leukemia in LMICs (+...)

Oncology News Blinatumomab Feasible for Children With Leukemia in LMICs A real-world study examines whether blinatumomab can be given safely and effectively to children with B-cell acute lymphoblastic leukemia at referral hospitals in lower-middle-income countries. Medscape Medical News, November 20, 2026 https://www.medscape.com/index/list_13474_0

Rett Syndrome

Rett Syndrome Rett syndrome is a rare, progressive neurodevelopmental disorder and a leading cause of severe intellectual disability in girls. Early diagnosis enables timely intervention, shifting care from supportive symptom management to emerging targeted therapies. https://www.medscape.org/advances/clinical-advances-rett-syndrome-2025a10007af

Colorectal Cancer Update: Integrating Emerging Science From the Annual European Oncology Meeting Into Community Practice Authors: Tiago Biachi de Castria, MD, PhD

https://www.medscape.org/viewarticle/colorectal-cancer-update-integrating-emerging-science-annual-2026a10016yz?page=1

Adjuvant Immunotherapy in High-Risk CSCC: What’s New, What’s Next, What Clinicians Need to Know Authors: Anna C. Pavlick, DO, MBA; Nina A. Ran, MD, MS, MPH

https://www.medscape.org/viewarticle/adjuvant-immunotherapy-high-risk-cscc-whats-new-whats-next-2026a10016zn?page=1

Eltrombopag Plus Cyclosporine for Moderate Aplastic Anemia: A Placebo-Controlled, Double-Blind Phase 3 Trial Authors: Britta Höchsmann, MD; Philippe Schafhausen, MD; Fabian Beier, MD; Michael Heuser, MD; Jörg Westermann, MD; Beatrice Drexler, MD; Alexander Röth, MD; Regina Herbst, MD; Mathias Hänel, MD; Michaela Schwarz, MD; Flore Sicre de Fontbrune, MD; Regis Peffault de Latour, MD, PhD; Astrid Marx-Hofmann, MD; Antonia Beitzen-Heineke, MD; Jens Panse, MD; Felicitas Thol, MD; Sixten Körper, MD; Tim H. Brümmendorf, MD; Hubert Schrezenmeier, MD

https://www.medscape.org/viewarticle/eltrombopag-plus-cyclosporine-moderate-aplastic-anemia-2026a10018f1?page=1

Modern Gastrointestinal Cancer Therapies

Modern Gastrointestinal Cancer Therapies As the therapeutic landscape for treating gastrointestinal cancer continues to grow and evolve, it is crucial for the oncology care team to remain up to date with the latest information. Our platform provides up-to-date resources to help optimize outcomes for your patients. https://www.medscape.org/advances/modern-gastrointestinal-cancer-therapies-2025a1000cys

Immunotherapy in Locally Advanced Head and Neck Cancer: Evidence, Impact, and Integration Authors: Hisham Mehanna, FMedSci, PhD, BMedSc (hons), MB ChB (hons), FRCS, FRCS (ORL-HNS); Robert Haddad, MD

https://www.medscape.org/viewarticle/immunotherapy-locally-advanced-head-and-neck-cancer-evidence-2026a1000khq?page=1&uac=148436CN&sso=true&src=mkmcmr_driv_stan_mscpedu_261120-OUS-HONC-immunotherapy-locally-advanced-head-and-neck-cancer-evidence-2026a1000khq-cta

jueves, 19 de noviembre de 2026

Tissue regeneration to help healing

Tissue regeneration to help healing Replacing damaged cells to treat injury and disease To stay alive, we have to replace cells that aren’t doing their job well, a process called regeneration. This Research in Context feature examines some of the ways NIH-supported scientists are trying to help our bodies do that through regenerative medicine. https://www.nih.gov/news-events/nih-research-matters/tissue-regeneration-help-healing

Our Innate Immune System Protects Us More Than We Knew

https://www.medscape.com/s/viewarticle/our-innate-immune-system-protects-us-more-than-we-knew-2026a10018n4?ecd=wnl_edit_tpal_etid8914816&uac=148436CN&impID=8914816 Our immune system has long been described as consisting of two parts. There’s the “innate” part that acts as a first-line defense but is often considered a blunt tool that responds to each threat the same way. And there’s the slow-acting “adaptive” part that remembers the microbes it encounters and builds lasting immunity against them.

After a GLP-1: Which Exit Strategy Keeps the Weight Off?

https://www.medscape.com/viewarticle/after-glp-1-which-exit-strategy-keeps-weight-2026a10018gh?ecd=WNL_trdalrt_pos1_ous_261118_etid8915401&uac=148436CN&impID=8915401 NATIONAL HARBOR, Md. — Among more than 20,000 patients who had taken semaglutide or tirzepatide, those who went on to pursue bariatric surgery, though the least likely choice, had the greatest weight loss after 2 years, while those who stopped treatment altogether had the least, new data show. “To our knowledge, this is the first study to compare weight change and cardiometabolic parameters across several obesity treatment strategies in patients who initially took injectable semaglutide or tirzepatide for obesity or type 2 diabetes,” Hamlet Gasoyan, DS, PhD, MPH, assistant professor of medicine, Cleveland Clinic Lerner College of Medicine of Case Western Reserve University, Ohio, told Medscape Medical News.

Diagnosing diabetes: the earlier the better The Lancet Diabetes & Endocrinology (++...)

Diagnosing diabetes: the earlier the better The Lancet Diabetes & Endocrinology https://www.thelancet.com/journals/landia/article/PIIS2213-8587(26)00277-9/fulltext?dgcid=raven_jbs_etoc_email In 2021, WHO launched the Global Diabetes Compact, an initiative aimed at reducing the risk of diabetes and ensuring that all people diagnosed with the condition have access to equitable, affordable, and high-quality care. The following year, the 75th World Health Assembly adopted the Compact's global diabetes coverage targets to be achieved by 2030—80% to be diagnosed; 80% to have good glycaemic control; 80% to have good blood pressure control; 60% of those aged 40 years and older to be receiving statins; and 100% of people with type 1 diabetes to have access to affordable insulin and blood glucose self-monitoring supplies. The need for such ambitious targets was borne out by a 2026 pooled analysis of individual-level data from national surveys in 100 low-income, middle-income, and high-income countries. The study found that, in 2021, of the included countries, only 8 met the target for diagnosis, 7 for glycaemic control, 15 for blood pressure control, and 8 for statin use, with attainment levels for all metrics lowest in low-income and middle-income countries (LMICs). If the 2030 targets are to be met, inequalities in attainment must be reduced and substantial progress made across all countries. https://www.thelancet.com/journals/landia/issue/vol14no12/PIIS2213-8587(26)X2010-1

Voices in Care: Multidisciplinary and Patient Perspectives on Advanced/Recurrent Endometrial Cancer Authors: Eva-Maria Strömsholm; Rebecca Kristeleit, MBChB, MRCP, PhD; Domenica Lorusso, MD, PhD; Antonio González-Martín, MD, PhD; Claire Lusted, ANP

https://www.medscape.org/viewarticle/voices-care-multidisciplinary-and-patient-perspectives-2026a1000hui?page=1&src=mkmcmr_driv_stan_mscpedu_261118-OUS-HONC-voices-care-multidisciplinary-and-patient-perspectives-2026a1000hui-cta&uac=148436CN

ADHD in an underserved context: how Chinese social media users discuss recognition, care, and difficulty Xueyan Cao1 , Yidi Wang2,* (++...)

https://www.academia.edu/2997-9196/3/3/10.20935/MHealthWellB8513 Introduction: Attention-deficit/hyperactivity disorder (ADHD) remains under-recognized and underdiagnosed in China, particularly among adolescents and adults. As formal diagnosis and treatment remain difficult to access, ADHD has become increasingly visible on social media platforms such as RedNote, where users share experiences, compare symptoms, and seek information outside clinical settings. Understanding how ADHD is discussed in these spaces is important for mental health literacy, stigma reduction, and pathways to care. Materials and methods: Using a computational approach, we examined how ADHD is discussed on Chinese social media. We analyzed 47,612 valid user comments from the 50 most-commented posts that were obtained through searching the keyword “ADHD” on RedNote. We used Structural Topic Modeling (STM) to identify latent thematic clusters and Semantic Network Analysis (SNA) to examine how key terms co-occurred across the corpus. Results: Four themes were identified: school difficulties and family communication; managing attention and task completion; clinical diagnosis and treatment; and academic performance and evaluation concerns. Clinical diagnosis and treatment was the most prevalent theme. The semantic network showed that “oneself” and “ADHD” were the most highly connected terms, and that diagnostic vocabulary co-occurred with everyday language about schooling, self-management, and family life. Conclusions: On RedNote, ADHD is discussed largely through the language of schooling, academic performance, and family life rather than in strictly clinical terms, with diagnostic language interwoven with first-person accounts of everyday difficulty. These patterns describe how ADHD is collectively discussed and can inform culturally grounded mental health communication and screening for digitally engaged populations. Future interview-based, longitudinal, and cross-platform research could test whether these patterns hold more broadly. https://www.academia.edu/journals/academia-mental-health-and-well-being/articles?source=journal-top-nav

Optimizing the Adult NF1 Journey: A Primary Care and Nonspecialist Guide to Surveillance Authors: Eric Legius, MD, PhD; Anna Berghoff, MD, PhD; Victor-Felix Mautner, MD, PhD; Ignacio Blanco, MD, PhD

https://www.medscape.org/viewarticle/optimizing-adult-nf1-journey-primary-care-and-nonspecialist-2026a1000zq3?page=1&src=mkmcmr_driv_stan_mscpedu_261117-OUS-HONC-optimizing-adult-nf1-journey-primary-care-and-nonspecialist-2026a1000zq3-cta&uac=148436CN

Home Gut Microbiome Tests Give Varying Results June 24, 2026 By: Stephanie Servetas

https://www.nist.gov/blogs/taking-measure/home-gut-microbiome-tests-give-varying-results Editor’s note: This blog post discusses the scientific study of fecal matter (aka poop). If that’s bothersome to you, you might want to skip this one (or at least not read it while eating). You may have heard about companies that claim they can give you lifestyle advice by analyzing a stool sample, similar to how you can decode your DNA with saliva. A team of microbiologists at NIST recently put these tests … well … to the test using precisely measured stool samples we already had in our labs.

The Gut Microbiome: Measuring Microbes and Setting Standards for Better Health

https://www.nist.gov/health/gut-microbiome-measuring-microbes-and-setting-standards-better-health Only about half of the cells in your body are human. The other half are trillions of microbes that thrive on or inside your body to form a group of biological communities known as the human microbiome. These microbial communities can vary greatly in size and character. The digestive tract hosts the largest number of microbes, forming a complex ecosystem known as the gut microbiome. Concentrated primarily in the large intestine, it consists of thousands of different species of bacteria, viruses, fungi and other microorganisms. Like a fingerprint, your gut microbiome is entirely unique. It starts developing the moment you are born. Over time, the amount and types of microorganisms change based on factors such as your environment and diet.

FDA Launches the Global Reliance Disclosure Program to Expand Patient Access to Medicines Worldwide

https://www.fda.gov/news-events/press-announcements/fda-launches-global-reliance-disclosure-program-expand-patient-access-medicines-worldwide?utm_medium=email&utm_source=govdelivery The GRDP launched on Oct. 30, with a President's Emergency Plan for AIDS Relief (PEPFAR) tentative approval for lenacapavir, a drug indicated for both HIV prevention and treatment. This is an especially meaningful starting point given PEPFAR's life-saving mission to combat HIV/AIDS in some of the world's most vulnerable populations. The GRDP is currently available to PEPFAR tentative approvals, excluding tentatively approved abbreviated new drug application products. However, the FDA intends to expand the GRDP in January 2027 to all novel drug and biologics (New Molecular Entity New Drug Applications and 351(a) Biologics License Applications), dramatically broadening the program's reach and impact. The FDA also intends to launch a pathway in early 2027 to expedite an applicant’s ability to request their minimally redacted action packages for approved and licensed drugs and biologics, accelerating global access to medicines that are already on the market in the United States and have been found to be safe and effective by the FDA. The GRDP addresses one of the most persistent and consequential challenges in global health: the gap between regulatory approval in high-capacity countries and patient access in lower-resource settings. When a drug is approved by the FDA, patients in many parts of the world may wait months or years longer for their own national health authority to complete an independent review due to limited regulatory capacity and resources. Beyond individual product approvals, the GRDP supports global health security. Harmonized regulatory decisions reduce the risk of fragmented or inconsistent product standards across markets, helping to ensure that the same high-quality therapies reach patients regardless of where they live, including here in the United States.

Yale study explores why arthritis returns after cancer immunotherapy

https://www.news-medical.net/news/20261118/Yale-study-explores-why-arthritis-returns-after-cancer-immunotherapy.aspx When arthritis develops during cancer immunotherapy, swollen hands can make it hard to open a jar or turn a doorknob. Inflammation in the knees can make walking difficult. For some patients, the joint pain and swelling ease, only to return. These subsequent flares can be severe enough to interrupt cancer immunotherapy, according to Sang Taek Kim, MD, PhD, assistant professor of medicine (rheumatology, allergy & immunology) at Yale School of Medicine, who notes that approximately 20% to 25% of cancer patients will have rheumatological adverse events after receiving immunotherapy. To better understand why the inflammation recurs, he and his colleagues examined what changed inside the joints between initial and subsequent flares. In their study, published in Cancer Immunology Research, the team found that some groups of immune cells present during the first flare had become numerous by the second flare. The pattern suggests that during the second occurrence of inflammatory arthritis, the immune system may be drawing on its memory of the earlier response. “When our immune system encounters the same antigens, those responses can get stronger,” explains Kim, who directs the Yale Immunotherapy Adverse Events in Rheumatology Program.

Study reveals the combined effect of migraine and smoking on premature stroke, mortality

https://www.news-medical.net/news/20261118/Study-reveals-the-combined-effect-of-migraine-and-smoking-on-premature-stroke-mortality.aspx Migraine and smoking were each associated with a higher risk of early stroke in people who had given birth, while participants with both had the highest risk, according to a study published November 18, 2026, in Neurology, the medical journal of the American Academy of Neurology. The study defined early stroke as occurring at age 60 or younger. Researchers also found that smoking was associated with a higher risk of death during the study, whether a person had migraine or not, while the combination of migraine and smoking was associated with the highest risk of death. The study does not prove migraine and smoking cause early stroke and death, it only shows associations.

Iron may cut childhood iron-deficiency anemia risk by 76%

https://www.news-medical.net/news/20261119/Iron-may-cut-childhood-iron-deficiency-anemia-risk-by-7625.aspx Data from more than 50,000 young people show that daily iron supplements could help tackle one of the world's most widespread nutritional disorders, while also revealing important gaps in our understanding of their safety and broader health benefits.

From paint thinners to fuels: Could workplace chemicals play a role in Parkinson’s disease?

https://www.news-medical.net/news/20261118/From-paint-thinners-to-fuels-Could-workplace-chemicals-play-a-role-in-Parkinsone28099s-disease.aspx An analysis of more than 41,000 people examines whether chemicals encountered in everyday industrial workplaces could help explain the origins of a neurological disease that often emerges decades later. In a recent study published in the journal Scientific Reports, researchers evaluated the association between occupational solvent exposure and Parkinson’s disease (PD) using data from the Parkinson’s Progression Markers Initiative (PPMI) Online study. Reported exposure to seven individual solvents was associated with higher odds of PD. When all 13 solvents were assessed simultaneously, positive associations persisted for kerosene, trichloroethylene (TCE), mineral spirits, and carbon tetrachloride. Participants reporting exposure to more solvents had progressively higher odds of PD. The findings identify occupational solvent exposure as a potentially modifiable risk factor for PD, but do not establish causality. Scientists from the School of Medicine and Health Sciences at Tecnológico de Monterrey and the Institute of Neurology and Neurosurgery at TecSalud’s Zambrano Hellion Medical Center in Mexico conducted the research.

Rethinking recruitment to clinical trials in Alzheimer's disease The Lancet Neurology (++...)

Rethinking recruitment to clinical trials in Alzheimer's disease The Lancet Neurology https://www.thelancet.com/journals/laneur/article/PIIS1474-4422(26)00406-0/fulltext?dgcid=raven_jbs_etoc_email Since the first regulatory approval of an anti-amyloid therapy in 2021, the number of clinical trials in Alzheimer's disease and of agents tested has continued to increase. According to the annual review of the Alzheimer's disease drug development pipeline, 158 agents were being tested in 192 phase 1–3 clinical trials in January 2026. The World Alzheimer Report 2026, A New Era in Dementia Clinical Trials, published by Alzheimer's Disease International in September, welcomes the vitality of this pipeline but warns that recruitment must improve for its promise to be fulfilled. The report is based on interviews with several dozen people living with dementia, their relatives, and clinical experts and aims to “demystify” clinical trials and to imrpove awareness of and trust in them. https://www.thelancet.com/journals/laneur/issue/vol25no12/PIIS1474-4422(26)X2010-5

Sending the right message The Lancet Psychiatry (++...)

Sending the right message The Lancet Psychiatry https://www.thelancet.com/journals/lanpsy/article/PIIS2215-0366(26)00299-3/fulltext?dgcid=raven_jbs_etoc_email The ODDESSI trial is a milestone for Open Dialogue research, being the first large-scale randomised controlled trial testing the Open Dialogue framework against treatment as usual for patients presenting with a mental health crisis. Executing such a trial within the English National Health Service mental health system was no easy feat, and pursuing more rigorous evidence for Open Dialogue in real-world conditions is commendable. The trial's principal finding was a null primary outcome and the main conclusion, supported by some positive secondary outcomes, was that more research is needed. Unfortunately, the landmark nature of the trial is being marred by confusing messaging. The consequences of this extend far beyond the ODDESSI trial. Inaccurate communication of published research can erode trust in science—from funders, policy makers, and the public—putting at risk investment in work necessary to build the evidence base and improve patients’ lives. It could also reduce the confidence and willingness of patients to participate in clinical trials. We would like to use this opportunity to remind the whole research community of the importance of a planned and balanced communication strategy. For the avoidance of doubt, not all these points apply to ODDESSI: our concern is for accurate reporting of all psychiatry research. https://www.thelancet.com/journals/lanpsy/issue/vol13no12/PIIS2215-0366(26)X2010-7

Oncology Cases & Quizzes Fast Five Quiz: Multiple Myeloma Management (+...)

Oncology Cases & Quizzes Fast Five Quiz: Multiple Myeloma Management How much do you know about the management of multiple myeloma? Test your knowledge with this quick quiz. Medscape Reference, November 19, 2026 1 https://www.medscape.com/index/list_12039_0

Oncology Perspective: Medscape Strategies for Administrative Workload Report 2026 (+...)

Oncology Perspective Medscape Strategies for Administrative Workload Report 2026 One third of physicians' time is spent on admin tasks each week, according to results of a Medscape survey. Doctors share their biggest pain points and potential solutions. Medscape, November 20, 2026 https://www.medscape.com/index/list_13293_0

Oncology News: Higher Melphalan Exposure Tied to Deeper Myeloma Responses (+...)

Oncology News Higher Melphalan Exposure Tied to Deeper Myeloma Responses A phase 1/2 trial explores dose and infusion schedule optimization of a propylene glycol-free melphalan formulation in patients with newly diagnosed myeloma undergoing autologous stem cell transplant. Medscape Medical News, November 19, 2026 https://www.medscape.com/index/list_13474_0

Three Antidepressants Show Superior Sustained Response in Major Depression

https://www.medscape.com/viewarticle/three-antidepressants-show-superior-sustained-response-major-2026a10018px?ecd=WNL_trdalrt_pos1_ous_261119_etid8918857&uac=148436CN&impID=8918857 A large comparative study of antidepressant medication has identified the drugs’ ability to achieve and sustain improvements in patients with major depressive disorder (MDD). The analysis showed that escitalopram, duloxetine, and agomelatine were associated with higher rates of sustained treatment response than those observed with fluoxetine. Escitalopram and duloxetine were also associated with lower rates of treatment discontinuation.

First drug for Lowe syndrome could soon reach clinical trials Patients could finally have a therapy available if the repurposed drug is successful. The trial protocol is under review with the Italian Medicines Agency. Written byAllison Whitten, PhD

First drug for Lowe syndrome could soon reach clinical trials Patients could finally have a therapy available if the repurposed drug is successful. The trial protocol is under review with the Italian Medicines Agency. Written byAllison Whitten, PhD https://www.drugdiscoverynews.com/first-drug-for-lowe-syndrome-could-soon-reach-clinical-trials-17672 The ultimate goal in drug discovery is to identify the mechanistic cause of a disease, develop a therapeutic to target it, and then test the efficacy in humans with the condition. But it’s rarely that easy, and each step can take years or even decades. Antonella De Matteis’ lab appears to be successfully following this path for Lowe syndrome, a rare X-linked disorder with mutations in the OCLR gene that causes issues with the eyes, brain, and kidneys. After 20 years of studying the mechanistic cause of the disease, her lab has now identified a novel biological cause behind the kidney disease aspect and demonstrated that a repurposed drug can target it in patient-derived cells, kidney organoids, and animal models. Their work was published recently in Signal Transduction and Targeted Therapy. The findings will likely lead to the first drug in clinical trials for Lowe syndrome, if the Italian Medicines Agency accepts the Phase 2 submission from Can-Fite BioPharma. ”We now finally have a tangible opportunity to offer people living with Lowe syndrome and their families, who have supported our work throughout these years, a real prospect for the future,” Leopoldo Staiano, a molecular biologist at the Telethon Institute of Genetics and Medicine and the CNR Institute of Genetic and Biomedical Research, and the first author of the study, said in the press release.

FDA Approves First Drug to Treat Neurological Symptoms of Type 3 Gaucher Disease

https://www.fda.gov/news-events/press-announcements/fda-approves-first-drug-treat-neurological-symptoms-type-3-gaucher-disease?utm_medium=email&utm_source=govdelivery The U.S. Food and Drug Administration has approved Infilbray (venglustat) tablets to treat neurological manifestations of Type 3 Gaucher disease (GD3) in adults and pediatric patients weighing at least 15 kg. This is the first approved therapy capable of crossing the blood-brain barrier to address the neurological symptoms of GD3, a rare and progressive condition that has long lacked effective treatment options for its most debilitating manifestations. Approval was supported by data from a randomized, double-blind, multicenter clinical study in which patients treated with Infilbray demonstrated clinically meaningful neurological improvement compared to those continuing enzyme replacement therapy over 52 weeks. Healthcare providers are encouraged to review the full prescribing information for complete details on indication, dosing, and important safety information, including important safety considerations related to mood changes, potential cataracts in pediatric patients, potential risks to the fetus in pregnancy, and potential drug interactions, when considering treatment for eligible patients. Cases of suicidal ideation and behavior have been reported in patients receiving Infilbray. Healthcare providers should assess psychiatric risk before starting treatment and monitor patients throughout therapy. Patients and caregivers should seek prompt medical attention if new or worsening depression or thoughts of self-harm occur.

Bladder Cancer Tumor Board: Optimizing Treatment Selection and Therapeutic Tolerability Authors: Andrea Necchi, MD; Thomas Powles, MBBS, MRCP, MD; Gaia Latini, MSN, RN

https://www.medscape.org/viewarticle/bladder-cancer-tumor-board-optimizing-treatment-selection-2026a1000r3y?page=1&src=mkmcmr_driv_stan_mscpedu_261118-OUS-HONC-bladder-cancer-tumor-board-optimizing-treatment-selection-2026a1000r3y-cta&uac=148436CN

Adjuvant Immunotherapy in High-Risk CSCC: What’s New, What’s Next, What Clinicians Need to Know Authors: Anna C. Pavlick, DO, MBA; Nina A. Ran, MD, MS, MPH

https://www.medscape.org/viewarticle/adjuvant-immunotherapy-high-risk-cscc-whats-new-whats-next-2026a10016zn?page=1&src=wnl_tpal_261118_mscpedu&uac=148436CN&impID=8916913

Refining Adjuvant Therapy in HR-Positive/HER2-Negative Early Breast Cancer: Personalizing Care in the CDK4/6 Inhibitor Era Authors: Nadia Harbeck, MD, PhD; Frédérique Penault-Llorca, MD; Giampaolo Bianchini, MD; Henry Cain, MBChB, FRCS, MD; Janice Walshe, MB BCh, BAO, MRCPI

https://www.medscape.org/viewarticle/refining-adjuvant-therapy-hr-positive-her2-negative-early-2026a1000ysl?page=1&uac=148436CN&src=mkmcmr_driv_stan_mscpedu_261118-OUS-HONC-refining-adjuvant-therapy-hr-positive-her2-negative-early-2026a1000ysl-cta

miércoles, 18 de noviembre de 2026

Fasting-Mimicking Diet vs. Calorie Restriction: Which Works Better for Weight Loss?

https://www.news-medical.net/health/Fasting-Mimicking-Diet-vs-Calorie-Restriction-Which-Works-Better-for-Weight-Loss.aspx Brief fasting-like cycles and sustained calorie reduction affect overlapping biological pathways, raising questions about how timing, protein intake, and refeeding shape their effects. Chronic caloric restriction (CCR) involves a sustained reduction in daily energy intake while maintaining adequate nutrition, whereas the fasting-mimicking diet (FMD) imposes substantial, often temporary, calorie restriction while permitting limited nutrient intake. A commonly studied FMD uses five consecutive days of restriction each month, emphasizing plant-based foods that reproduce selected fasting-related metabolic effects without complete food deprivation. These approaches differ in the timing and intensity of energy restriction, dietary composition, and whether they include refeeding periods between FMD cycles.1,2,5 Periodic FMD cycles may activate adaptive metabolic and cellular responses, including reduced insulin-like growth factor 1 (IGF-1) signaling, ketogenesis, and cellular stress responses, whereas CCR restricts intake continuously, rather than in discrete cycles. Both approaches can influence nutrient-sensing pathways and metabolic risk factors, with the cumulative energy deficit dependent on intake throughout the intervention, including FMD refeeding periods. FMD may be more acceptable for some individuals. To date, neither better adherence nor metabolic superiority over CCR has been established. Human studies report improvements in body mass index (BMI), waist circumference, and metabolic risk factors, though heterogeneous designs and dropout rates limit conclusions about superiority over CCR. Evidence from other intermittent fasting schedules provides context; however, it cannot establish the comparative effects of FMD.1,2,3,4

What Health Benefits Can Silkworm Protein Powder Offer? Reviewing the Evidence

https://www.news-medical.net/health/What-Health-Benefits-Can-Silkworm-Protein-Powder-Offer-Reviewing-the-Evidence.aspx From silk production to protein supplements, silkworm pupae are drawing scientific attention for their nutritional composition and the biological activity of their peptides. Introduction & Sustainable Protein Context Entomophagy, the consumption of edible insects, includes the established use of silkworm (Bombyx mori) pupae as food in several Asian countries.1,4 The silkworm is an economically important lepidopteran insect best known for silk production. While silkworm pupae are sometimes discarded as waste or used in animal feed or manure, they also have a history of human consumption. Current research examines their use in protein-rich food ingredients, rather than treating them solely as a waste stream.1 Silk reeling leaves the silkworm pupa as a byproduct from which silkworm pupa protein (SPP) can be extracted, typically through alkali extraction and acid precipitation. Limitations of these methods include wastewater generation and changes in protein conformation that can affect emulsifying and foaming properties. Organic solvents may also be used separately, including for defatting; however, their use is distinct from alkali extraction and acid precipitation.1

Does Losing One Sense Make Other Senses Stronger?

https://www.news-medical.net/health/Does-Losing-One-Sense-Make-Other-Senses-Stronger.aspx What happens in the brain when sight or hearing fades, and why do some remaining sensory abilities become sharper? "Sensory compensation" describes neural and behavioral adaptations that support interaction with the environment after impairment of a primary sensory modality. Losing vision or hearing, for example, can improve performance on certain tasks that rely more on the remaining senses; however, these benefits vary by individual and task. Compensation is often incomplete, and sensory loss can continue to limit everyday functioning.1,2

Can microplastics get under your skin? What everyday exposure could mean for your health

https://www.news-medical.net/news/20261117/Can-microplastics-get-under-your-skin-What-everyday-exposure-could-mean-for-your-health.aspx From cosmetics and synthetic clothing to airborne pollution, researchers examine how everyday exposure to tiny plastic particles could affect the skin and whether certain populations face greater risks. The term microplastics was introduced in 2004, and since then, these particles have been detected in various parts of the body, including human blood, lung, and placental tissue. In a recent narrative review published in the American Journal of Clinical Dermatology, researchers examined existing evidence on how these particles reach the skin and whether they contribute to skin disease.

Personalized vaccines work, making them is the hard part The science behind personalized mRNA cancer vaccines is working. Building a different drug for every patient, at scale, is the real fight. Written byAndrea Corona

Personalized vaccines work, making them is the hard part The science behind personalized mRNA cancer vaccines is working. Building a different drug for every patient, at scale, is the real fight. Written byAndrea Corona https://www.drugdiscoverynews.com/personalized-vaccines-work-making-them-is-the-hard-part-17504?utm_campaign=DDN_Newsletter_Dose&utm_medium=email&_hsenc=p2ANqtz-_YKyHbNCHJSI9Ha9CKBzZEcjwWLivbWWFZ5weD7dOaOpqiUdRm6h5fvJV8tr3ahBWYPYTlehApHi0KOVXD_3BRiacQSw&_hsmi=449776666&utm_content=449776666&utm_source=hs_email

AI-based analysis offers new roadmap for precision oncology The new approach combined digital pathology with spatial proteomics to uncover the secrets of metastasis and personalized treatment options. Written byAllison Whitten, PhD

AI-based analysis offers new roadmap for precision oncology The new approach combined digital pathology with spatial proteomics to uncover the secrets of metastasis and personalized treatment options. Written byAllison Whitten, PhD https://www.drugdiscoverynews.com/ai-based-analysis-offers-new-roadmap-for-precision-oncology-17460?utm_campaign=DDN_Newsletter_Dose&utm_medium=email&_hsenc=p2ANqtz-8LIehaN3cuMKhf44TpuDaCIzGuw3LCMND0KegpmAAT284K8D3j5Pvo7CQMKvIPDKutXUaS8XSMkC4bvyU0MClaeq4EOQ&_hsmi=449776666&utm_content=449776666&utm_source=hs_email How and why a tumor metastasizes — when a seemingly similar tumor doesn’t — remains one of the biggest questions in cancer research. New research from György Marko-Varga’s lab at Lund University with Istvan Nemeth at the Szeged Clinical hospital, and Peter Horvath’s team at HUN-REN Biological Research Centre suggests a new way to chip away at this question with the help of AI combined with spatial proteomics to reveal the single-cell dynamics of different populations of cancer cells within the same tumor. Their approach offers a promising step up over traditional molecular analyses that view the entire tissue sample at once and miss the functional differences in how different cell types behave. In their case report of a young woman with metastasized melanoma, the researchers identified two spatially distinct tumor cell populations in the original tumor. One, PT1, was an aggressive melanoma subtype that likely drove metastasis into the lungs and eventually the brain. Their analysis also surfaced metabolic and kinase programs associated with the progression and treatment resistance, which suggested that targeted therapies may not work well for the patient, with metabolic inhibitors potentially offering greater gains for the patient. “These findings demonstrate the potential of patient-specific AI-imaging interfaced with proteomic tumor mapping to move beyond conventional pathology, reveal actionable vulnerabilities, and guide more precise combination treatment strategies for advanced melanoma,” Marko-Varga told DDN.

Unexpected approach could crack key cancer signaling pathway Cancer researchers have attempted to target the WNT pathway for decades without success due to severe toxicity issues. A new paper could solve that problem. Written byAllison Whitten, PhD

https://www.drugdiscoverynews.com/unexpected-approach-could-crack-key-cancer-signaling-pathway-17660 For decades, targeting the WNT signaling pathway in cancer has eluded drug developers. That’s because while it’s a crucial pathway that drives uncontrolled cell division and tumor growth, it’s also essential in maintaining homeostasis in normal healthy tissues. Thus, any therapeutic that targets WNT and harms cancer cells also harms healthy cells, leading to severe toxicity and intolerable side effects in preclinical models. For example, a common strategy has been to target a pair of enzymes that regulate the WNT pathway, TNKS1 and TNKS2. But earlier work with dual inhibitors led to gastrointestinal damage in animal models. Now, Lukas Dow’s lab at Weill Cornell Medicine may have found a surprising way around these harsh side effects. His lab first built genetic tools to silence TNKS1 and TNKS2 independently of each other rather than silencing both. “When we started using them in cancer cell lines we noticed something unexpected: In some cases, suppressing TNKS2 alone was sufficient to suppress WNT,” Dow told DDN. In a new paper published in Nature Chemical Biology, Dow’s team generated a first-in-class TNKS2 inhibitor and showed that it successfully inhibited WNT signaling in TNKS1-deficient cell and organoid models.

From a patient’s discovery to a potential new treatment for ulcerative colitis What began with a patient's search for relief from ulcerative colitis has become a biotech's effort to turn a botanical discovery into a drug. Written byBree Foster, PhD

From a patient’s discovery to a potential new treatment for ulcerative colitis What began with a patient's search for relief from ulcerative colitis has become a biotech's effort to turn a botanical discovery into a drug. Written byBree Foster, PhD https://www.drugdiscoverynews.com/from-a-patient-s-discovery-to-a-potential-new-treatment-for-ulcerative-colitis-17653 When Julie Saiki was diagnosed with ulcerative colitis (UC), she was pursuing a PhD in musicology — and certainly was not planning to found a biopharmaceutical company. However, she quickly found that standard treatments did not work for her. She is not alone in this, as 16 percent of patients with moderate-to-severe UC do not respond to first-line treatments such as corticosteroids. Eventually, her search for relief led her to indigo naturalis, a botanical extract used in traditional Chinese medicine.

FDA grants accelerated approval to neladalkib for previously treated locally advanced or metastatic ALK-positive non-small cell lung cancer

https://www.fda.gov/drugs/cancer-approvals/fda-grants-accelerated-approval-neladalkib-previously-treated-locally-advanced-or-metastatic-alk?utm_medium=email&utm_source=govdelivery On November 17, 2026, the Food and Drug Administration granted accelerated approval to neladalkib (Nelkarmi, Nuvalent, Inc.), a kinase inhibitor, for adults with locally advanced or metastatic anaplastic lymphoma kinase (ALK)-positive non-small cell lung cancer (NSCLC) who have previously received the following therapy in the unresectable locally advanced or metastatic setting: one prior ALK tyrosine kinase inhibitor (TKI) consisting of alectinib, or two or more prior ALK TKIs and platinum-based chemotherapy.

FDA Approves First Drug Shown to Help Patients with Infantile-Onset Niemann-Pick Disease Type C Live Longer New therapy offers a meaningful treatment option for families facing a rare and serious childhood disease

https://www.fda.gov/news-events/press-announcements/fda-approves-first-drug-shown-help-patients-infantile-onset-niemann-pick-disease-type-c-live-longer?utm_medium=email&utm_source=govdelivery The FDA has approved Lembaz (adrabetadex), the first treatment shown to reduce the risk of death in patients with infantile onset Niemann-Pick disease type C (NPC), a rare inherited disease that causes progressive neurological decline. Lembaz is approved for patients who weigh at least 7 kg (about 15 pounds) and whose neurological symptoms began before age 6, also known as infantile onset. It is given as an injection into the spinal canal every two weeks. Patients treated with Lembaz had longer overall survival compared to the matched external control group, with a 55% reduction in the risk of death. The median survival time was 8.5 years for the treated group compared with 4.9 years in the control group. The most common side effects include problems with hearing, balance and coordination, fatigue, vomiting, back pain, headache, fever, diarrhea, nausea, and cough. Lembaz carries a boxed warning for hearing impairment, including permanent hearing loss, and patients should have a comprehensive hearing evaluation before starting Lembaz and regularly throughout treatment. Lembaz received Breakthrough Therapy designation. The FDA granted approval of Lembaz to Mandos, LLC, a subsidiary of Beren Therapeutics, PBC.

martes, 17 de noviembre de 2026

Oncology News: LUGPA 2026 - Q&A: Why the Jury Is Still Out on Durvalumab for NMIBC (+...)

Oncology News LUGPA 2026 Q&A: Why the Jury Is Still Out on Durvalumab for NMIBC Despite a recent FDA approval, urologic oncologists are waiting for more data before embracing durvalumab add-on for patients with high-risk non-muscle invasive bladder cancer. Medscape Medical News, November 17, 2026 https://www.medscape.com/index/list_13474_0

Newer GLP-1 drugs to combat obesity may be the next global battleground over access to medicines, expert warns LSE professor Ken Shadlen argues drugmakers should ready licensing plans now

https://www.statnews.com/pharmalot/2026/11/16/semaglutide-obesity-glp1-access-medicines-low-income-countries/ By Ed SilvermanNov. 16, 2026 Pharmalot Columnist, Senior Writer Over the past few months, lower-cost generic versions of the blockbuster GLP-1 drug semaglutide, which is sold as Wegovy by Novo Nordisk for combating obesity, started to become available in some countries and will soon arrive in still others. Meanwhile, the pharmaceutical industry is racing to develop newer GLP-1 medicines that, to varying degrees, are forecast to be more effective, cause fewer side effects, and are easier to administer.

Sellas’ experimental blood cancer immunotherapy reduced risk of death in clinical trial The unexpected result is good news for patients with acute myeloid leukemia

https://www.statnews.com/2026/11/17/sellas-blood-cancer-immunotherapy-succeeds-clinical-trial/ By Adam FeuersteinNov. 17, 2026 Adam Feuerstein, a senior writer and biotech columnist, is the author of Adam’s Biotech Scorecard, a subscriber-only newsletter about the crossroads of drug development, business, Wall Street, and biotechnology.

Obesity Week 2026 (+...)

https://www.medscape.com/c25/p14/obesity-week-2026-2026a100159b?ecd=wnl_conf_endo_obesity-week_SPON_261116_mscpedit_etid8908796&uac=148436CN&impID=8908796

American Society For Reproductive Medicine (ASRM) 2026 (+...)

https://www.medscape.com/c25/p14/american-society-reproductive-medicine-asrm-2026-2026a10010mu?ecd=wnl_conf_obgyn_ASRM_SPON_261116_mscpedit_clihub_etid8898607&uac=148436CN&impID=8898607

Bispecific ADCs could unlock thousands of new cancer targets A logic-gated platform is expanding what's druggable in antibody-drug conjugate development by pairing antigens that cancer cells co-express but normal tissue does not. Written byAndrea Corona

Bispecific ADCs could unlock thousands of new cancer targets A logic-gated platform is expanding what's druggable in antibody-drug conjugate development by pairing antigens that cancer cells co-express but normal tissue does not. Written byAndrea Corona https://www.drugdiscoverynews.com/bispecific-adcs-could-unlock-thousands-of-new-cancer-targets-17476?utm_campaign=DDN_Newsletter_Dose&utm_medium=email&_hsenc=p2ANqtz-8BeCXrQ-kYqh0UDGsFW7MsK5S6FQvFNM2yshB0EKBOjmiPy3resXW8MMGgE5U4hZMtrWJ9y-Kdj3UkCYCJSzwHoXlf2A&_hsmi=449562183&utm_content=449562183&utm_source=hs_email Antibody-drug conjugates have transformed oncology over the past decade, but they have been working with a limited playbook. The same small set of validated ADCs — including HER2, TROP2, NECTIN4, cMET and a few others — has anchored most ADC programs, not because researchers lack ambition, but because the biology of what makes a safe ADC target is genuinely constrained. Promatix Biosciences, a UK-based biotech, is attempting to expand that constraint using a proteomics-driven cis-bispecific discovery platform. By identifying pairs of antigens that are co-expressed on cancer cells but rarely co-expressed in normal tissue, the company aims to move ADC development from a field limited by target scarcity to one enriched with first-in-class target combinations to evaluate.

A new vulnerable window of time to prevent metastasis Researchers showed that before cancer cells metastasize the brain, they enter a “proliferative pause” that can be targeted with drugs to prevent metastasis altogether. Written byAllison Whitten, PhD

A new vulnerable window of time to prevent metastasis Researchers showed that before cancer cells metastasize the brain, they enter a “proliferative pause” that can be targeted with drugs to prevent metastasis altogether. Written byAllison Whitten, PhD https://www.drugdiscoverynews.com/a-new-vulnerable-window-of-time-to-prevent-metastasis-17576?utm_campaign=DDN_Newsletter_Dose&utm_medium=email&_hsenc=p2ANqtz--5xJFKUe1c0pEgYx56iaabLCBR01JpR7Kzyeh3mEnyH2Pc8odWiuLU1ClsfE7K36DGfYgQ6UoIhVdJ9KbRlJMqPhEY8w&_hsmi=449562183&utm_content=449562183&utm_source=hs_email Cancer cells that migrate and attempt to metastasize a new organ do not receive a warm welcome. Instead, they must adapt to new conditions that often require changing their metabolism and reorganizing their DNA. The majority of them die. Those that survive create a new tumor, separate from the original, that must be eradicated through treatment as well. But some scientists are taking a different approach. “Why not, instead of treating established metastasis, try to prevent metastasis?” Manuel Valiente, a neuroscientist and brain cancer researcher at the Spanish National Cancer Research Centre, said to DDN. In a new paper published in Cancer Cell, Valiente’s team showed for the first time that there is a uniquely vulnerable time where prevention might be possible. “Unexpectedly, we have found that very aggressive cancer cells, metastatic cells that make it all the way to the brain, when they get in, they have to stop their aggressive nature for some time,” explained Valiente.

Unexpected approach could crack key cancer signaling pathway Cancer researchers have attempted to target the WNT pathway for decades without success due to severe toxicity issues. A new paper could solve that problem. Written byAllison Whitten, PhD

Unexpected approach could crack key cancer signaling pathway Cancer researchers have attempted to target the WNT pathway for decades without success due to severe toxicity issues. A new paper could solve that problem. Written byAllison Whitten, PhD https://www.drugdiscoverynews.com/unexpected-approach-could-crack-key-cancer-signaling-pathway-17660 For decades, targeting the WNT signaling pathway in cancer has eluded drug developers. That’s because while it’s a crucial pathway that drives uncontrolled cell division and tumor growth, it’s also essential in maintaining homeostasis in normal healthy tissues. Thus, any therapeutic that targets WNT and harms cancer cells also harms healthy cells, leading to severe toxicity and intolerable side effects in preclinical models. For example, a common strategy has been to target a pair of enzymes that regulate the WNT pathway, TNKS1 and TNKS2. But earlier work with dual inhibitors led to gastrointestinal damage in animal models. Now, Lukas Dow’s lab at Weill Cornell Medicine may have found a surprising way around these harsh side effects. His lab first built genetic tools to silence TNKS1 and TNKS2 independently of each other rather than silencing both. “When we started using them in cancer cell lines we noticed something unexpected: In some cases, suppressing TNKS2 alone was sufficient to suppress WNT,” Dow told DDN.

iPLEDGE Risk Evaluation and Mitigation Strategy (REMS) (+++...)

https://www.fda.gov/drugs/postmarket-drug-safety-information-patients-and-providers/ipledge-risk-evaluation-and-mitigation-strategy-rems?utm_medium=email&utm_source=govdelivery iPLEDGE REMS Modifications Have Been Implemented and Are Live for Isotretinoin, a Medication for Severe Acne The iPLEDGE Risk Evaluation and Mitigation Strategy (REMS) modifications were implemented yesterday, November 15, 2026. The iPLEDGE REMS is a safety program to mitigate the risk of isotretinoin, which can result in harm to fetal development. Isotretinoin is approved to treat severe nodular acne that has not responded to other treatments in non-pregnant patients 12 years and older. The modifications aim to minimize the burden on patients, prescribers, and pharmacies while maintaining the safe use of isotretinoin. Important information is summarized below. Important information for patients: Enrolled patients do not need to re-enroll in the iPLEDGE REMS and can continue using the REMS system through their existing accounts. Prior to starting treatment with isotretinoin, patients must complete the required pregnancy tests in a medical setting. If permitted by a prescriber, patients may complete subsequent monthly pregnancy tests outside of a medical setting (e.g., using home pregnancy tests) during and after treatment with isotretinoin. If a person who can get pregnant does not pick up their prescription within 7 days of their last negative pregnancy test, a repeat pregnancy test may be done immediately without an additional waiting period. https://ipledgeprogram.com/#Main Important information for prescribers: Prescribers do not need to re-enroll or re-certify in the iPLEDGE REMS with this modification and can continue using the REMS system through their existing accounts and established workflows. Prescribers should continue to follow existing annual re-certification timelines. Prescribers do not need to update or change the assigned patient categories for enrolled/active patients. Prior to starting treatment with isotretinoin, patients must complete the required pregnancy tests in a medical setting. Prescribers may opt to allow patients to complete subsequent monthly pregnancy tests outside of a medical setting (e.g., using home pregnancy tests) during and after treatment. Prescribers will need to establish processes and procedures to minimize misinterpretation and falsification of pregnancy tests that patients complete outside of a medical setting. If a person who can get pregnant does not pick up their prescription within 7 days of their last negative pregnancy test, a repeat pregnancy test may be done immediately without an additional waiting period. If the patient has not started isotretinoin, the repeat pregnancy test must be done in a medical setting. Patients who cannot get pregnant must be counseled at enrollment. Monthly documentation of counseling in the iPLEDGE REMS for patients who cannot get pregnant is no longer required. Prescribers should reinforce counseling throughout the course of treatment. https://ipledgeprogram.com/#Main Important information for pharmacies: Pharmacy-authorized representatives do not need to re-enroll or re-certify in the iPLEDGE REMS with this modification and can continue using the REMS system through their existing accounts and established workflows. Pharmacy-authorized representatives should continue to follow existing annual re-certification timelines. There is no longer a 30-day prescription window for patients who cannot get pregnant. Pharmacies may need to adapt their workflow practices to ensure that, if a patient does not pick up the prescription, the authorization is reversed in the REMS and the prescription is returned to stock. Clarifying language was added to the REMS to communicate that pharmacy staff training is required annually and the certified pharmacy’s authorized representative should maintain records of training completion. https://ipledgeprogram.com/#Main https://www.fda.gov/drugs/postmarket-drug-safety-information-patients-and-providers/questions-and-answers-ipledge-rems?utm_medium=email&utm_source=govdelivery

ESMO ASIA 2026 INDUSTRY SATELLITE SYMPOSIUM Shaping the Future of HER2-Mutated Advanced NSCLC: Precision Strategies Across the Continuum CME Suntec Singapore Convention & Exhibition Centre Friday, 4 December 2026 | 12:30 - 14:00 SGT

https://events.medscapelive.org/website/100421/?utm_campaign=449165.01a_inperson_awarenessemail&utm_source=lbu-edu&utm_medium=em&utm_content=ext&ecd=em_ext_261116_lbu-edu_449165.01-44916501ainpersonawarenessemail_ Recent breakthroughs in HER2-directed therapies are transforming the standard of care for patients with HER2-mutated advanced non–small cell lung cancer (NSCLC). Join our distinguished panel of experts for a highly engaging symposium to learn more about the effective implementation of novel, evidence-based therapeutic strategies and how to optimally manage your patients across the care continuum. IMPORTANT NOTICE: To attend this symposium in person, you must register directly with the ESMO ASIA CONGRESS 2026. Please visit the official congress website for more details.

Reshaping Rare Disease Care: Integrating Real-World Evidence and the Patient Voice in PNH and ITP Authors: Danny Hsu, MBBS, FRACP, FRCPA; Ana Boban, MD, PhD; Maria L. Lozano, MD, PhD

https://www.medscape.org/viewarticle/reshaping-rare-disease-care-integrating-real-world-evidence-2026a1000oio?page=1&src=mkmcmr_driv_stan_mscpedu_261116-OUS-HONC-reshaping-rare-disease-care-integrating-real-world-evidence-2026a1000oio-cta&uac=148436CN

FDA approves giredestrant in combination with everolimus for ER-positive, HER2-negative, ESR1-mutated locally advanced or metastatic breast cancer

https://www.fda.gov/drugs/cancer-approvals/fda-approves-giredestrant-combination-everolimus-er-positive-her2-negative-esr1-mutated-locally?utm_medium=email&utm_source=govdelivery On November 16, 2026, the Food and Drug Administration approved giredestrant (Wilserdly, Genentech, Inc.), an oral estrogen receptor antagonist, in combination with everolimus for the treatment of adults with estrogen receptor (ER)-positive, human epidermal growth factor receptor 2 (HER2)-negative, estrogen receptor 1 (ESR1)-mutated locally advanced or metastatic breast cancer, as detected by an FDA-authorized test, whose disease has recurred during or after completion of endocrine-based adjuvant therapy, or has progressed on at least one endocrine-based regimen in the metastatic setting.

Widely used antidepressant outperformed by 3 other drugs in major study of 30,000 people (+...)

Widely used antidepressant outperformed by 3 other drugs in major study of 30,000 people https://www.foxnews.com/health Widely used antidepressant outperformed by 3 other drugs in major study of 30,000 people Researchers compared fluoxetine with 20 other antidepressants to determine how well they eased symptoms By Kelly McGreal Fox News Published November 16, 2026 1:51pm EST https://www.foxnews.com/health/widely-used-antidepressant-outperformed-3-other-drugs-major-study-30000-people Drinking 6 to 8 cups of tea a day linked to lower risk of serious diseases, massive study finds https://www.foxnews.com/lifestyle

No end to tuberculosis without women and children The Lancet Microbe (++...)

No end to tuberculosis without women and children The Lancet Microbe https://www.thelancet.com/journals/lanmic/article/PIIS2666-5247(26)00242-9/fulltext?dgcid=raven_jbs_etoc_email When Robert Koch identified the cause of tuberculosis in 1882, the disease killed one in seven people in Europe and the USA. Today, 1·23 million people die from tuberculosis each year, and an estimated 336 900 pregnant and postpartum women develop tuberculosis, as do 1·1 million children younger than 15 years. Since 2014, WHO’s End TB Strategy has guided the interventions, but progress has been uneven and insufficient to reach the global targets. In this November issue, we publish a Series of four papers on advances in the epidemiology, diagnosis, treatment, and prevention of tuberculosis. https://www.thelancet.com/journals/lanmic/issue/vol7no11/PIIS2666-5247(26)X2010-9

Beyond declarations: ending early and forced marriage in Southeast Asia The Lancet Regional Health – Southeast Asia (++...)

Beyond declarations: ending early and forced marriage in Southeast Asia The Lancet Regional Health – Southeast Asia https://www.thelancet.com/journals/lansea/article/PIIS2772-3682(26)00180-0/fulltext?dgcid=raven_jbs_etoc_email This year, the UN General Assembly declared Nov 27 the International Day for the Elimination of Child, Early and Forced Marriage. The resolution is especially relevant to south Asia, home to 290 million people married before the age of 18 years, which is 45% of the global total. The region has witnessed change over the past decade, with the likelihood of marriage before age 18 falling from 46% to 26%. In India, data from the National Family Health Survey (NFHS) paints a promising picture: among interviewed women (aged 20–24 years), the proportion of those married before age 19 declined from 47.4% in NFHS-3 to 22.3% in NFHS-5 (2019–2021). Rates are lower in Thailand (2022) and Sri Lanka, where only 17% and 10% of girls, respectively, marry before age 18. However, gains are uneven at the subnational and regional level. Several Indian states, including Assam, Manipur, and Tripura, recorded increases in early marriage between NFHS-4 and NFHS-5, and about half of young women in Bangladesh still marry when minors. https://www.thelancet.com/journals/lansea/issue/vol54nonull/PIIS2772-3682(26)X2009-1

FDA approves new breast cancer drug, providing new option for some patients, boost for Roche Company believes therapy could become its top-selling product, though estimates vary

https://www.statnews.com/2026/11/16/fda-approves-new-roche-breast-cancer-drug/ By Andrew JosephNov. 16, 2026 Europe Correspondent

After death in gene therapy trial for a brain disease, progress is reported Capsida scientists suggest they have found better way to test risk in monkeys

https://www.statnews.com/2026/11/17/capsida-gene-therapy-trial-death-follow-up-investigation/ By Jason MastNov. 17, 2026 General Assignment Reporter https://www.statnews.com/2025/12/15/gene-therapy-capsida-biotherapeutics-clinical-trial-death-ramifications/

Flavored nicotine tablets, the tobacco industry’s latest product, worry public health advocates Experts say the tablets’ resemblance to mints could make them appealing to kids

https://www.statnews.com/2026/11/17/zyn-melts-tobacco-firms-test-market-nicotine-pouch-alternatives/ By Kathryn Kranhold — The ExaminationNov. 17, 2026 https://www.theexamination.org/articles/zyn-melts-nicotine-tablets-kids?utm_source=stat&utm_medium=referral&utm_campaign=syndication

Faith-based addiction recovery groups don’t often get federal funding. RFK Jr. wants to change that Experts agree faith can aid recovery but worry whether evidence-based treatment will be offered

https://www.statnews.com/2026/11/17/rfk-jr-federal-funding-faith-based-recovery-groups/ By Theresa GaffneyNov. 17, 2026 Addiction Reporter

Webinar: CamRARE's Passport in Action Online event Wednesday, November 25 • 10 AM - 11 AM GMT-3 / (+ + +... 11 videos +))

https://www.eventbrite.co.uk/e/webinar-camrares-passport-in-action-tickets-2003004888541?utm_term=0_-33a3a608a7-461549513&mc_cid=618dbe5b55&mc_eid=937637ee49&utm_campaign=618dbe5b55-EMAIL_CAMPAIGN_2025_05_30_05_40_COPY_01&utm_medium=email&utm_source=Network+News&aff=oddtdtcreator Learn more about the CamRARE's Rare Patient Passport in action across the globe Join us on 25 November, 1:00–2:00 pm for a free webinar exploring the journey of CamRARE’s Rare Patient Passport since its creation. We’ll look at how the Passport has grown from a tool for rare disease patients into an increasingly global resource, with more patient groups adopting it, and its use expanding across healthcare settings—particularly in Australia. We’ll also share an exciting update on the beginnings of translating the Passport, helping to make it accessible to even more rare disease communities around the world. Come along to hear how the Passport is being used in practice, what’s next for its development, and how it is helping rare disease patients communicate their needs across different healthcare settings. CamRARE's 1 in 17 Challenge Online event Monday, November 30 • 10 AM - 11 AM GMT-3 https://www.eventbrite.co.uk/e/camrares-1-in-17-challenge-tickets-2004005893574?utm_term=0_-33a3a608a7-461549513&mc_cid=618dbe5b55&mc_eid=937637ee49&utm_campaign=618dbe5b55-EMAIL_CAMPAIGN_2025_05_30_05_40_COPY_01&utm_medium=email&utm_source=Network+News&aff=oddtdtcreator 17 My Way – What's next for the 1 in 17 Challenge? 17 My Way – What's next for the 1 in 17 Challenge? Register for our online session on 30 November and help us shape what happens next. This will be an opportunity to share our plans, hear your ideas, answer your questions and explore how we can work together to make the challenge a meaningful and impactful campaign. This is a year-long campaign that raises awareness of rare conditions, amplifies the voices of those affected and brings people together through storytelling, community engagement and fundraising. At the heart of the campaign is the estimated statistic that 1 in 17 people will be affected by a rare condition during their lifetime. Behind that number are millions of individual stories, experiences and journeys. By sharing these stories, we can help more people understand the realities of living with a rare condition and support CamRARE’s work through our Unique Feet community. Whether you have a personal connection to rare conditions, want to support someone you care about, or represent an organisation that would like to get involved, there is a place for you in this campaign. RAREsummit26 de Cambridge Rare Disease Network (CamRARE) (11 videos) https://www.youtube.com/playlist?list=PLAylbwAKedsY Genetic Alliance UK is an alliance of over 220 organisations, charities and support groups working together to improve the lives of everyone in the UK living with genetic, rare and undiagnosed conditions. https://geneticalliance.org.uk/who-we-are/